Akanda Corp. (AKAN)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.84
- As of
Kresmion compiles this page from AKAN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AKANDA CORP. (AKAN): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-30.
See the full AKAN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AKAN on one page. Preview it with sample data, then open it live with a free account.
Preview the AKAN dossierActive events for AKAN
No recent events on AKAN in the last 180 days.
FREE, NO ACCOUNT
Every event on AKAN, as it fires
New filings, 13F moves and cross asset events on AKAN land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, AKAN
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
Going concern statement
AKAN's 6-K filed Sep 30, 2026 states:
These conditions raise substantial doubt about our ability to continue as a going concern.
Read the 6-K on SEC EDGAR Every company with a going concern statement
More data on AKAN
AKAN mentioned in Kresmion daily briefs
AKAN against its peers
AKAN's operating margin of -523.8% ranks in the 21st percentile of 6 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-09-30.
| Metric | AKAN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 836664 USD | 16.5M USD | 21 | 6 |
| Revenue YoY | -61.3% | n/a | n/a | 1 |
| Gross margin | 24.9% | 61.8% | 6 | 8 |
| Operating margin | -523.8% | -14.1% | 21 | 6 |
| Net margin | -489.6% | -20.4% | 19 | 7 |
| Return on equity | -95.8% | -17.4% | 7 | 6 |
Peers (8): UPC, AYTU, HYEX, INIS, YCBD, BIOE, GELS, MCUJF. Left out: CABR (period gap), BFRI (period gap), CNTMF (no annual filing), OPTH (no annual filing), TRUFF (no annual filing), INM (period gap), TXMD (period gap), ROMJF (no annual filing), SNOA (period gap), CPHI (period gap), SHPH (period gap), ETST (period gap), MRMD (period gap), PLNH (period gap), ITHUF (period gap), IXHL (period gap), HSTI (period gap). Fiscal periods ending between 2024-12-31 and 2025-09-30. Every figure is one full fiscal year read from one annual filing (AKAN: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in AKAN on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on AKAN in the last 180 days.
Upstream: SEC EDGAR filings for AKAN
Kresmion, "AKANDA CORP. (AKAN) institutional holdings and SEC filings", data as of 2026-09-30, https://kresmion.com/research/AKAN. Upstream data: SEC EDGAR filings for AKAN.
Link to this data (HTML):
<a href="https://kresmion.com/research/AKAN">AKANDA CORP. (AKAN) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow AKAN on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to AKAN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.